Targeting prion amyloid deposits in vivo

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 7, 2004, Pages 775-784

  Sadowski, Marcin ^a   Pankiewicz, Joanna ^a   Scholtzova, Henrieta ^a   Tsai, Julia ^a   Li, Yongsheng ^a   Carp, Richard I ^b   Meeker, Harry C ^b   Gambetti, Pierluigi ^c   Debnath, Manik ^d   Mathis, Chester A ^d   Shao, Li ^d   Gan, Wen Biao ^a   Klunk, William E ^d   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid; Imaging; Methoxy X04; Prion; Scrapie; Two photon microscopy

Indexed keywords

AMYLOID; AMYLOID PROTEIN; CONGO RED; FLUORESCENT DYE; METHOXY X04; PRION PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CELL LABELING; CELL SPECIFICITY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; IMAGE ANALYSIS; IN VIVO STUDY; LIGAND BINDING; MEMBRANE PERMEABILITY; MICROSCOPIC ANATOMY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRION DISEASE; PRIORITY JOURNAL; SCRAPIE; SYMPTOMATOLOGY;

EID: 3042755626     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.7.775     Document Type: Article

References (51)

1. Prusiner SB. Neurodegenerative diseases and prions. N Eng J Med 2001;344:1516-26
2. Wisniewski T, Sigurdsson EM, Aucouturier P, Frangione B. Conformation as a therapeutic target in the prionoses and other neurodegenerative conditions. In: Baker HF, ed. Molecular and cellular pathology in prion disease. Totowa, New Jersey: Humana Press, 2001:223-36
3. Zerr I, Poser S. Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests. APMIS 2002;110:88-98
4. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol 2001;56:1143-53
5. Sadowski M, Kumar A, Wisniewski T. Prion diseases. In: Bradley WG, ed. Neurology in clinical practice. Butterworth-Heinemann, 2004:1613-30
6. Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci USA 1999;96:15137-42
7. Britton TC, Al-Sarraj S, Shaw C, Campbell T, Collinge J. Sporadic Creutzfeldt-Jakob disease in a 16-year-old in the UK. Lancet 1995;346:1155
8. Hilton DA, Ghani AC, Conyers L, et al. Accumulation of prion protein in tonsil and appendix: Peview of tissue samples. Brit Med J 2002;325:633-34
9. Spinney L. vCJD epidemic could be first of many, experts warn. Nature Med 2003;9:1096
10. Llewelyn CA, Hewitt PE, Knight RSG, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-21
11. Aucouturier P, Kascsak RJ, Frangione B, Wisniewski T. Biochemical and conformational variability of human prion strains in sporadic Creutzfeldt-Jakob disease. Neurosci Lett 1999;274:33-36
12. DeArmond SJ, Kretzschmar H, Prusiner SB. Prion diseases. In: Graham DI, Lantos P, eds. Greenfield's neuropathology. London: Arnold, 2002:273-324
13. Ma JY, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 2002;298:1781-85
14. Ma JY, Lindquist S. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci USA 2001;98:14955-60
15. DeArmond SJ, Prusiner SB. Prion protein transgenes and the neuropathology in prion diseases. Brain Pathol 1995;5:77-89
16. Ward HJT, Head MW, Will RG, Ironside JW. Variant Creutzfeldt-Jakob disease. Clin Laboratory Med 2003;23:87-98
17. Merz PA, Wisniewski HM, Somerville RA, Bobin SA, Masters CL, Iqbal K. Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques. Acta Neuropathol 1983;60:113-24
18. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Eng J Med 2003;349:583-96
19. Mathis CA, Wang YM, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of C-11-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-54
20. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab 2002;22:1035-41
21. Klunk WE, Bacskai BJ, Mathis CA, et al. Imaging A beta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002;61:797-805
22. Bruce ME, Dickinson AG. Genetic control of amyloid plaque production and incubation period in scrapie-infected mice. J Neuropathol Exp Neurol 1985;44:285-94
23. Gibson PH. Distributions of amyloid plaques in 4 regions of the brains of mice infected with scrapie by intracerebral and intraperitoneal routes of injection. Acta Neuropathol 1986;69:322-25
24. Jeffrey M, Goodsir CM, Bruce M, McBride PA, Scott JR, Halliday WG. Correlative light and electron-microscopy studies of PrP localization in 87V scrapie. Brain Res 1994;656:329-43
25. Kim JI, Ju WK, Choi JH, et al. Expression of cytokine genes and increased nuclear factor-kappa B activity in the brains of scrapie-infected mice. Mol Brain Res 1999;73:17-27
26. Lee DW, Sohn HO, Lim HB, et al. Alteration of free radical metabolism in the brain of mice infected with scrapie agent. Free Radical Res 1999;30:499-507
27. Kim YS, Carp RI, Callahan S, Wisniewski HM. Incubation periods and histopathological changes in mice injected stereotaxically in different brain-areas with the 87V scrapie strain. Acta Neuropathol 1990;80:388-92
28. Aucouturier P, Geissmann F, Damotte D, et al. Infected dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. J Clin Invest 2001;108:703-8
29. Carp RI, Callahan SM, Sersen EA, Moretz RC. Preclinical changes in weight of scrapie-infected mice as a function of scrapie agent-mouse strain combination. Intervirology 1984;27:61-69
30. Sigurdsson EM, Brown DR, Daniels M, et al. Vaccination delays the onset of prion disease in mice. Am J Pathol 2002;161:13-17
31. Soto C, Kascsak RJ, Saborio GP, et al. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet 2000;355:192-97
32. Wong BS, Venien-Bryan C, Williamson RA, et al. Copper refolding of prion protein. Biochem Biophys Res Commun 2000;276:1217-24
33. Liu T, Zwingman T, Li R, et al. Differential expression of cellular prion protein in mouse brain as detected with multiple anti-PrP monoclonal antibodies. Brain Res 2001;896:118-29
34. Sigurdsson EM, Sy MS, Li RL, et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett 2003;336:185-87
35. Bresjanac M, Smid LM, Vovko TD, Petric A, Barrio JR, Popovic M. Molecular-imaging probe 2-(1-{6-[(2-fluoroethyl)(methyl)amino]-2-naphthyl} ethylidene) malononitrile labels prion plaques in vitro. J Neurosci 2003;23:8029-33
36. Grutzendler J, Kasthuri N, Gan WB. Long-term dendritic spine stability in the adult cortex. Nature 2002;420:812-16
37. Christie RH, Games D, Seubert P, Schenk D, Hyman BT. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-72
38. Sadowski M, Tang CY, Aguinaldo JG, Carp R, Meeker HC, Wisniewski T. In vivo micro magnetic resonance imaging signal changes in scrapie infected mice. Neurosci Lett 2003;345:1-4
39. Morton DB, Griffiths PH. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet Record 1985;116:431-36
40. Stokes A. Humane endpoints in animal experiments for laboratory animals used in toxicity testing. Proceedings of the 3rd World Congress on Alternatives and Animal Use in Life Sciences, held in Bologna, Italy, August 29-September 2, 1999
41. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 2003;100:12462-67
42. Mathis CA, Bacskai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorganic Med Chem Lett 2002;12:295-98
43. DeKosky ST, Marek K. Looking backward to move forward: Early detection of neurodegenerative disorders. Science 2003;302:830-34
44. Klunk WE, Engler H, Nordberg A, et al. Imaging the pathology of Alzheimer's disease: Amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am 2003;13:781-95
45. Green AJE, Ramljak S, Muller WEG, Knight RSG, Schroder HC. 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein. Neurosci Lett 2002;324:57-60
46. Budka H, Hainfellner HA. The human prion diseases: Neuropathology, pathobiology and molecular genetics. Vienna, Austria, 16 October 1995. Neuropathol Appl Neurobiol 1996;22:171-73
47. Hainfellner JA, Brantnerinthaler S, Cervenakova L, et al. The original Gerstmann-Straussler-Scheinker family of Austria: Divergent clinicopathological phenotypes but constant PrP genotype. Brain Pathol 1995;5:201-11
48. Zeidler M, Johnstone EC, Bamber RWK, et al. New variant Crutz-feldt-Jakob disease: Psychiatric features. Lancet 1997;350:908-10
49. Bateman D, Hilton D, Love S, Zeidler M, Beck J, Collinge J. Sporadic Creutzfeldt-Jakob disease in a 18-year-old in the UK. Lancet 1995;346:1155-56
50. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19
51. Klunk WE, Wang YM, Huang GF, et al. The binding of 2-(4′- methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-92